Issue 2/2024
Todorova-Stefanova1, I, Genkova2,
K., Petrova2, G.
1 Clinic of Pediatrics, UMBAL „Alexandrovska“
2 Department of Pediatrics, Medical University – Sofia
Severe asthma in childhood represents a significant burden on patients and society. It is broadly defined as asthma requiring GINA step 4 and 5 therapy in the previous year or needing systemic corticosteroids for 6 months to prevent exacerbations or asthma that remains uncontrolled despite this therapy. Although biologic therapy has been available for the treatment of asthma in adults and adolescents for nearly 20 years, studies of the efficacy and safety of these molecules in children have lagged behind. This trend has changed in recent years grace to the greater number and increasing availability of biologics, both by expanding age indications and by developing new therapies.
Key words: biomarkers, severe asthma, phenotype
Address for correspondence:
Тоdorova-Stefanova, I.
Clinic of Pediatrics, UMBAL „Alexandrovska“
11, „Acad. Ivan Geshov“, Blvd.
1612, Sofia